lobbying_activities: 2025497

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2025497	f7d6f86b-4e75-489c-93eb-b788ce3dc79e	Q3	WINNING STRATEGIES WASHINGTON	50796	KALEO	2017	third_quarter	PHA	Pharmaceutical drug development including epinephrine for anaphylaxis	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE	30000		0	0	2017-10-16T14:57:04.083000-04:00